Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3297 participants.

Also called NCT01720446

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,297 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01720446
  • EudraCT 2012-002839-28
Other papers using this trial's data
  • Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes The New England journal of medicine, 2016-11-10 DOI, PubMed 27633186
  • Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6) Diabetes, obesity & metabolism, 2020-08 DOI, PubMed 32227613, PMC7383680 In the PMC Open Access subset under CC BY-NC.
  • Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy Diabetes, obesity & metabolism, 2018-04 DOI, PubMed 29178519, PMC5888154 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Algeria, Argentina, Australia, Brazil, Bulgaria, Canada, Denmark, Germany, India, Israel, Italy, Malaysia, Mexico, Poland, Russia, Spain, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01720446. Randomized; double masking; primary purpose treatment. Start 2013-02-21 (actual); primary completion 2016-03-15 (actual). Results posted on 2018-03-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
Acronym
SUSTAIN™ 6
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
semaglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01720446
Content hash
991cc507330eb2d94864909807c1e4d5bf9806b62d42863b4408e7123d393f56